Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: Potential contributing mechanism of benefit in acute coronary syndromes
Yf. Li et al., Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: Potential contributing mechanism of benefit in acute coronary syndromes, J THROMB TH, 10(1), 2000, pp. 69-76
The glycoprotein (GP) IIb/IIIa receptor antagonists used widely in the medi
cal treatment of acute coronary syndromes and during percutaneous coronary
interventions, prevent fibrinogen cross-linking and platelet aggregation, c
ritical initiating steps in arterial thrombosis. Their anticoagulant proper
ties, particularly when administered conjunctively with heparin preparation
s, are less well-characterized. In a series of in vitro studies, increasing
concentrations of abciximab, tirofiban, and eptifibatide either alone or i
n combination with unfractionated heparin (UFH) or fractionated heparin (en
oxaparin) were added to washed platelets suspended in Tyrode's buffer. Foll
owing platelet activation and prothrombinase assembly, thrombin generation
was determined by enzyme-linked immunosorbent assay (ELISA). There was a co
ncentration-dependent reduction in platelet-dependent thrombin generation w
ith each of the GPIIb/IIIa receptor antagonists. The combination of tirofib
an and UFH yielded percent, absolute and relative reductions (compared with
tirofiban alone) of 48.0%, 16.9%, and 35.2%, respectively. The correspondi
ng values for eptifibatide and abciximab were 38.0%, 13.5%, 35.5%, and 55.1
%, 3.8%, 8.4%, respectively. Thrombin generation was decreased by an additi
onal 2 to 3% (absolute reduction) with high concentrations of enoxaparin in
combination with either eptifibatide or abciximab. Platelet GPIIb/IIIa rec
eptor antagonists, beyond their ability to prevent fibrinogen-mediated aggr
egation, inhibit platelet-dependent prothrombinase activity and thrombin ge
neration in a concentration-dependent manner. Heparin facilitates the exist
ing anticoagulant properties, supporting combination therapy in clinical pr
actice. The potential added benefit of fractionated heparin over UFH will r
equire further investigation.